NurExone Biologic Inc. (OTC: NRXBF) Stock Gains Momentum: Now What?

There are a lot of options for investors who may be looking into the biopharmaceutical sector at this point, and in light of recent events, it could be a good move to possibly take a look into NurExone Biologic Inc. (OTC: NRXBF). On April 25, the company came into focus among investors after it announced that its common shares had started trading on the OTCQB Venture Market under the ticker symbol NRXBF. It was a significant new milestone for the company since the listing would boost the visibility of the stock and enable its trading by United States institutional investors as well as retail investors.

The company also revealed that it had been awarded Depository Trust Company (DTC) eligibility for its shares listed on the OTCQB. Eligibility would be an important attribute for the shares since it would help in the expansion of their reach to a larger pool of potential investors as well as brokerage firms that demand higher compliance measures. The move would help the company enhance the accessibility of its shares and could also help strengthen liquidity.

The chairman of the NurExone Biologic Board, Yoram Drucker, spoke about the latest milestone from the company yesterday. He noted that being listed on the OTCQB and being awarded DTC eligibility were both demonstrations of the company’s commitment to strengthening shareholder liquidity and engagement. These two developments would help investors in the United States access the shares easily and make investments if they feel so. The Chief Executive Officer of NurExone Biologic, Dr. Lior Shaltiel, also expressed his views about the whole thing. He asserted that the expansion of the company’s investor base would help speed up NurExone Biologic’s efforts in the development of therapies and solutions for patients suffering from spinal cord injuries all over the world.